License Agreement (PDF)
Completion of this licensing agreement transferring copyright ownership to Formulary, is required and has to be signed by all article coauthors (a separate form for each author/coauthor of a single manuscript, each showing an original signature is required). The copyright form must not include any written notations other than the original written and printed signature of the author and date. This form should be mailed [not emailed or faxed] to Formulary when the article is submitted for publication consideration.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
